Sharechat Logo

Celo says healthcare platform is secure against cyber-threats such as KRACK vulnerability

Wednesday 18th October 2017

Text too small?

Technology startup Celo, which recently teamed with Roche NZ, says its healthcare data platform is secure against cyber-threats including those that exploit the key reinstallation attack weakness, or KRACK, that may leave devices vulnerable when accessing Wi-Fi networks. 

"There are ways of getting into environments that are not secure and so security is really where our strengths are," Celo chief executive Stephen Vlok told BusinessDesk. The Celo system, which allows users to communicate with each other, send documents, photographs and patient details, uses industry compliant encrypted technology that is designed in line with mobile banking, he said.

According to the government's Computer Emergency Response Team, a series of Wi-Fi vulnerabilities have been identified and are collectively referred to as KRACK or key reinstallation attack. These vulnerabilities affect MacOS, Windows, iOS, Android and Linux internet-connected devices.

Health-care providers are "crying out for this tool" as they are currently using texting, emails and phone calls and lack a secure way to communicate about their patients, said Vlok. The advantage is that Celo provides secure communication for clinicians to "immediately reduce the current risk of patient information, including images, being exchanged on phones," he said. 

Celo and Roche NZ have joined together in a recent innovation partnership to make Celo's secure messaging platform available for some New Zealand Society of Oncology members to pilot this year, using its recently launched Smart Oncology Network, or SONet. The SONet project is a collaboration between the NSCO, Celo and Roche NZ. 

Roche NZ is essentially providing funding for the NZSO's regular subscription to the platform, said Vlok. "The pilot period is an opportunity to get the oncology network going and get oncologists talking to one another," he said.  It also gives Celo an opportunity to obtain added functionality and insight into the particular characteristics of oncology. The aim is that the network will then move to an institutional license provided by the district health boards, he said.  

Having a secure network is seen as vital. "Modern cancer research is conducted by a multidisciplinary team of clinicians and scientists spread across our country. We need a tool that enables us to communicate to the whole team in real-time and still keep each patient's data 100 percent safe," said Ben Lawrence, medical oncologist and president of NZSO. 

Roche NZ medical manager Stuart Ryan also said that data protection is essential as personal, internet-based messaging and email services "pose special risks when patient health information is being discussed or exchanged. And people rightly expect high levels of data protection."

Vlok said there is international interest in its technology and the company is focused on Australia, the UK, Canada and Singapore. 

(BusinessDesk)

 

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Govt opts for sweeping review of 'underperforming' RMA
AFT gains Australian registration for intravenous Maxigesic
24th July 2019 Morning Report
Should Fletcher Building persist with Australia?
NZD weaker as greenback gains on news US-China trade talks to recommence
MARKET CLOSE: NZ shares extend gain as Mainfreight, A2 hit new highs
StretchSense directors appoint administrators
NZ dollar falls on news RBNZ is looking at "unconventional" policy
Wrightson capital return gets shareholder approval
Morrison & Co eyes asset sales from first PIP Fund

IRG See IRG research reports